What Ibogaine Is
Ibogaine is an indole alkaloid found primarily in the root bark of Tabernanthe iboga, a shrub native to the rainforests of Central and West Africa — principally Gabon, Cameroon, and the Republic of Congo. It also occurs in smaller concentrations in several related Apocynaceae species, including Voacanga africana and Tabernaemontana undulata. The compound was first isolated by French and Belgian chemists in 1901 and investigated sporadically through the early twentieth century before interest in its anti-addictive properties emerged in the 1960s.
Ibogaine is structurally classified as a tryptamine but pharmacologically unique: its mechanism of action spans multiple receptor systems simultaneously, differentiating it fundamentally from serotonergic psychedelics like psilocybin and LSD. It is both psychoactive and, at relevant doses, a genuine medical intervention requiring clinical-level screening and monitoring. The distinction between ibogaine as a sacramental practice and ibogaine as a pharmacological treatment for addiction is real but the safety considerations apply in both contexts: the same compound, at comparable doses, produces the same cardiac risks regardless of setting.
Total alkaloid extracts from T. iboga root bark (often called "TA" extract) contain ibogaine alongside other iboga alkaloids — notably ibogaline and ibogamine — and are used in traditional Bwiti ceremony. Pure ibogaine hydrochloride (HCl) is the form used in most clinical and harm-reduction contexts, as it allows precise dosing. Voacanga africana-derived total alkaloid preparations are also commercially available as legal precursors in some jurisdictions, though their alkaloid composition differs from T. iboga.
History & Cultural Roots
Iboga has been at the centre of Bwiti — a complex spiritual and initiation tradition practiced by the Bwiti people (principally the Mitsogho, Fang, and related groups) of Gabon and southern Cameroon — for centuries, and possibly millennia. In Bwiti initiation, very large doses of root bark — sufficient to produce an intense multi-day experience — are administered as a rite of passage: a crossing into relationship with ancestors, a confrontation with death and rebirth, and an initiation into adult spiritual life. The experience is inseparable from its ceremonial structure: music, song, fire, collective witnessing, and the guidance of trained initiates (ngangas) who navigate the journey alongside the initiant.
Bwiti is a living, sovereign tradition — not a relic. The Bwiti people's custodianship of iboga knowledge, their land, and the iboga plant itself are matters of cultural rights and political self-determination. The commercialisation of iboga in the Western addiction treatment and psychedelic tourism industries has raised serious concerns among Bwiti knowledge holders about epistemic extraction and cultural appropriation, even as demand from outside Africa has intensified pressure on wild iboga populations already affected by habitat loss. Gabonese iboga has been listed by the Gabonese government as a national cultural and heritage resource; the country has restricted export of raw iboga material in response to international demand.
Western discovery of ibogaine's anti-addictive properties is attributed to Howard Lotsof, a heroin-dependent man who in 1962 consumed ibogaine recreationally and found that his opioid craving had disappeared. Lotsof spent decades advocating for clinical research and developing treatment protocols, receiving several patents for ibogaine's use in addiction treatment. The US government classified ibogaine as a Schedule I substance in 1970 as part of the Controlled Substances Act, effectively preventing clinical research there — most of the subsequent development of ibogaine treatment has occurred in Europe, Canada, Mexico, and more recently New Zealand.
How Ibogaine Works
Multi-receptor pharmacology
Ibogaine's pharmacology is extraordinarily complex and not fully characterised. Its known mechanisms include: antagonism at NMDA glutamate receptors (which may contribute to its dissociative and oneirogenic qualities); agonism at kappa-opioid receptors (contributing to intense imagery and, in some models, to its anti-addictive effects); modulation of sigma receptors; antagonism at nicotinic acetylcholine receptors; and serotonin reuptake inhibition. It also affects sodium channels in the heart — the mechanism underlying its most serious risk — and is metabolised hepatically to noribogaine, an active metabolite with a much longer half-life (days to weeks) that continues exerting effects after ibogaine itself has cleared.
Unlike serotonergic psychedelics, ibogaine is not primarily a 5-HT2A agonist and produces phenomenological effects quite unlike those of psilocybin or LSD. Its kappa-opioid and NMDA-antagonist actions are thought to be more central to its unusual experiential profile — the waking dream state, the life review quality, and the atypical visual phenomenology.
The interruption of opioid dependence
Ibogaine's most clinically significant property is its capacity to dramatically reduce or eliminate opioid withdrawal symptoms and interrupt physical opioid dependence following a single dose. The precise mechanism remains under active investigation. Noribogaine's long-acting effects at opioid receptors likely contribute. Current models propose that ibogaine resets opioid receptor sensitivity and modulates the neural circuits of habit and craving — particularly in the ventral tegmental area and nucleus accumbens — through a combination of NMDA antagonism, kappa-opioid activity, and glutamate system normalisation. The result, observed consistently across clinical and observational studies, is an interruption of withdrawal within hours and a reduction in craving that can persist for weeks to months following a single treatment session.
18-MC and the non-psychedelic derivative
18-Methoxycoronaridine (18-MC), a synthetic iboga alkaloid congener developed by Stanley Glick, retains anti-addictive properties without the psychedelic experience and, crucially, without the cardiac effects. It is in Phase II clinical trials. Its development is partly motivated by the hope of producing an FDA-approvable anti-addiction medicine without the safety and regulatory challenges of ibogaine itself — though some researchers and practitioners believe the psychedelic experience is itself therapeutically necessary, not a side effect to be engineered away.
Effects
Three phases of the experience
The ibogaine experience is characteristically divided into three overlapping phases. The acute phase (roughly hours 1–8) involves intense oneiric (waking dream) visual phenomena — vivid, autonomous imagery distinct from the geometric or emotional visuals of serotonergic psychedelics, often described as panoramic scenes, memories, or mythological narratives playing out with unusual clarity and apparent significance. These visuals occur with eyes open or closed and are accompanied by significant ataxia (loss of coordination) and often nausea or vomiting. The physical incapacitation during the acute phase is such that most people are bed-bound; attempting to walk without support is dangerous. Sound is typically amplified — sometimes painfully so — and music becomes intensely meaningful.
The evaluative phase (hours 8–20) tends to shift from autonomous visual phenomena toward introspection and what is widely described as a "life review" — a panoramic revisiting of significant memories, relationships, and patterns in one's history, often with a quality of emotional perspective or detachment not available in ordinary consciousness. Many people describe this as the therapeutically significant portion of the experience: a kind of inventory of one's life, with material surfacing that feels relevant to patterns of use, relational dynamics, or unresolved grief.
The residual stimulation phase can persist for 24–48 hours beyond the acute experience. People often find sleep impossible for the first night or two. There is a characteristic reflective openness during this window — energy, mental clarity, and emotional accessibility — that many providers regard as a primary integration opportunity. Total duration from ingestion to return to baseline sleep capacity: typically 24–36 hours, occasionally longer. This is substantially longer than any commonly used serotonergic psychedelic.
Phenomenological character
Ibogaine's phenomenological character is distinctive and should not be assimilated to the psilocybin or ayahuasca experience. The waking dream state is autonomous and image-driven in a way that many people describe as less controllable than serotonergic psychedelic experiences. The life review quality is widely reported but variable — some people experience it centrally, others less so. Physical symptoms (ataxia, nausea, sensitivity to light and sound) are more prominent than in most serotonergic psychedelic experiences. Confrontation with difficult emotional and biographical material is characteristic and should be anticipated rather than feared — preparation to receive and work with this material is part of responsible ibogaine therapy.
Dosage Reference
These ranges apply to pure ibogaine hydrochloride administered in clinical or medically supervised contexts. Root bark extracts are not reliably dose-calculable by weight. This table is reference information, not a recommendation.
| Level | Ibogaine HCl (by body weight) | Character |
|---|---|---|
| Low / test dose | 1–3 mg/kg | Mild psychoactive effects. Used to assess sensitivity and cardiac response before full dose. |
| Sub-flood (psychoactive) | 5–8 mg/kg | Significant psychedelic effects without complete flood experience. Used in some protocols for psychological work. |
| Flood dose (addiction interruption) | 10–20 mg/kg | Full experience; typical clinical dose for opioid dependence interruption. Maximum cardiac risk occurs at this range. |
Flood doses are weight-adjusted and should only be administered in settings with cardiac monitoring equipment and personnel capable of managing arrhythmia. A test dose administered 24–48 hours before a full flood dose allows assessment of QTc interval response. No responsible ibogaine provider should administer a flood dose without a baseline ECG, full contraindication screening, and continuous cardiac monitoring capability during the session.
What the Research Shows
Opioid use disorder
The evidence base for ibogaine's anti-addictive effects is substantial but consists primarily of observational studies, case series, and open-label trials rather than randomised controlled trials — largely because Schedule I status and safety concerns have made RCTs extremely difficult to conduct. Nonetheless, the consistency of findings across studies, countries, and decades is striking. A landmark Stanford-affiliated study published in Nature Medicine (Cherian et al., 2024) examined outcomes in veterans treated with ibogaine at a clinic in Mexico and found large reductions in PTSD symptom severity, depression, and anxiety — an extraordinary effect size in a difficult-to-treat population. Alper and colleagues' review of global case reports and observational data found that approximately half of opioid-dependent individuals who underwent ibogaine treatment reported no withdrawal symptoms and significant reductions in craving, with some maintaining abstinence at follow-up periods of months to years. Mash and colleagues' observational data from Bahamian and Caribbean treatment centres found comparable patterns across hundreds of patients.
The durability of ibogaine's anti-addictive effects appears highly variable and dependent on post-treatment support. People who receive ibogaine without accompanying psychological support, integration therapy, or ongoing community resources tend to have higher relapse rates than those who enter structured aftercare. Ibogaine interrupts the physical dependence and acute craving — it does not resolve the social, psychological, and environmental drivers of addiction that will continue to operate in the post-treatment period.
PTSD, depression, and TBI
The Stanford Nature Medicine study (2024) examined a cohort of special operations veterans treated at a legally operating ibogaine clinic in Mexico, finding dramatic reductions not only in PTSD symptoms but in suicidality, functional disability, and cognitive performance on neuropsychological testing. These findings generated significant attention given the treatment-resistant profile of the population and the scale of effect sizes reported. Controlled replication is urgently needed. Several institutions are currently developing ibogaine research programmes, including MAPS and academic centres in Canada, Switzerland, and New Zealand.
Microdosing iboga
Sub-perceptual doses of iboga root bark, used within Bwiti practice for maintenance and community ceremonies rather than initiation, have attracted interest from harm reduction and addiction communities. Observational data suggest that low-dose iboga may help maintain abstinence after a flood-dose treatment. This is a poorly studied area and not a substitute for medical management of addiction or psychiatric conditions.
Risks & Cardiac Safety
Ibogaine prolongs the QTc interval of the cardiac cycle — the period during which the heart's electrical system resets between beats. QTc prolongation increases the risk of ventricular arrhythmias, including Torsades de Pointes and ventricular fibrillation, which can cause sudden cardiac death. This is not a theoretical risk: ibogaine-associated deaths have occurred and are documented in the literature. Estimates of treatment-associated mortality vary but the most cited figure is approximately 1 in 300 treatments in contexts without adequate medical screening — a rate that is substantially reduced, but not eliminated, by proper cardiac screening and monitoring. There is no safe unsupervised ibogaine use at flood doses.
Absolute cardiac contraindications
Any pre-existing prolonged QTc interval (above 450ms in men, 470ms in women) is an absolute contraindication. Structural heart disease, arrhythmias, heart failure, and a family or personal history of sudden cardiac death also represent absolute contraindications. Before any flood-dose ibogaine administration, a 12-lead ECG is mandatory. Electrolyte imbalances — particularly low potassium or magnesium, which are common in people with substance use disorders — must be corrected before treatment, as electrolyte abnormalities independently increase arrhythmia risk and potentiate ibogaine's cardiac effects.
Drug interactions
QTc-prolonging medications — including methadone, SSRIs, antipsychotics, and others — can be fatal in combination with ibogaine. Review all medications with a physician before any ibogaine treatment.
View full drug interaction chart →Methadone, in particular, significantly prolongs QTc and the combination with ibogaine represents a substantial cardiac risk. Methadone-maintained individuals typically require a medically supervised taper to shorter-acting opioids (most often buprenorphine) before ibogaine treatment — a process that itself requires medical management. SSRIs, TCAs, antipsychotics, and many other medications also prolong QTc and require careful assessment. Stimulants — particularly cocaine and methamphetamine — present cardiovascular risks in the ibogaine context. The combination with MAOIs (present in ayahuasca) is dangerous and should be avoided.
Psychological risks
The ibogaine experience is intense and often psychologically demanding. People with active psychosis or schizophrenia spectrum conditions should not receive ibogaine. Severe, untreated mood disorders warrant careful assessment. The life review nature of the experience means that traumatic material frequently surfaces — integration support before and after is not optional for responsible practice.
Iboga plant sustainability
Wild Tabernanthe iboga populations are under pressure from overharvesting driven by international demand. The slow growth rate of the plant (root bark of therapeutic potency requires 7–10+ years of growth) and habitat loss in Central Africa have created a genuine sustainability crisis. Responsible engagement with ibogaine means giving weight to sourcing: providers and individuals who use cultivated or sustainably sourced iboga, or who work with Voacanga africana-derived total alkaloid preparations or synthetic ibogaine where clinically equivalent, contribute less to this pressure.
Legal Status
United States: Schedule I controlled substance. No legal therapeutic use. Research possible only with DEA Schedule I researcher licence — a significant barrier. Underground treatment exists but carries both legal and safety risk.
Canada: Not currently scheduled under the Controlled Drugs and Substances Act, placing it in a regulatory grey area. Clinical research and some treatment contexts operate with relative legal freedom, though the regulatory landscape is evolving.
New Zealand: Reclassified as a Class C substance in 2009, permitting use in authorised treatment settings. The most permissive regulatory environment for ibogaine treatment among English-speaking countries.
Mexico: Not scheduled. Numerous ibogaine treatment centres operate legally, making Mexico the primary destination for Americans seeking ibogaine treatment. Quality and safety standards vary enormously between providers.
Netherlands, Portugal, Brazil, and several other countries: Not scheduled or in grey areas that permit clinical and retreat use. UK, most of Europe, and Australia: Controlled substance; illegal without specific licence.
Accessing Ibogaine Treatment Safely
For individuals considering ibogaine for opioid dependence or other indications, the most important decision is the choice of provider. This is a context where quality of screening and medical oversight is literally a matter of survival.
The GITA (Global Ibogaine Therapy Alliance) has developed safety guidelines and a provider directory. MAPS and related harm reduction organisations have published screening protocols. Minimum safety standards include: mandatory pre-treatment ECG; measurement and correction of electrolyte levels; comprehensive medication review and washout; continuous cardiac monitoring during the session; appropriate emergency equipment (defibrillator) and trained personnel; a structured integration programme before and after treatment; and a licensed medical professional present or immediately available throughout. Any provider who cannot demonstrate these standards should not be trusted with flood-dose ibogaine administration.
The MAPS-sponsored Phase 2 trial of ibogaine is currently recruiting at sites in the United States, and academic research programmes at NYU, Johns Hopkins, and several Canadian universities are active. Clinical trial participation, where accessible, offers the highest-safety research-grade screening and monitoring.
Frequently Asked Questions
Ibogaine is not a cure for opioid addiction — that framing misrepresents what the research shows and sets people up for disappointment. What ibogaine can do, reliably and distinctively, is interrupt physical opioid dependence and dramatically reduce acute withdrawal symptoms following a single treatment. Many people report significantly reduced or absent craving for weeks to months afterward. However, addiction is not solely physical dependence: its psychological, social, and environmental drivers remain after ibogaine, and relapse rates without aftercare support are high. The most responsible framing is that ibogaine is a powerful pharmacological interruption that creates a window of opportunity — what is done in that window determines long-term outcomes.
Methadone and buprenorphine are evidence-based opioid agonist therapies — they reduce craving and withdrawal by substituting a longer-acting, medically managed opioid. They are highly effective at reducing overdose mortality and improving quality of life, and represent the gold standard of opioid use disorder treatment. Ibogaine is pharmacologically opposite in its approach: a single high-dose treatment that interrupts physical dependence rather than managing it on an ongoing basis. These are different interventions with different profiles of evidence, risk, and appropriate use. For some people, ibogaine offers a path that agonist therapy alone has not — but these approaches can also be sequenced and combined (with careful attention to the methadone-to-buprenorphine-to-ibogaine transition process when needed). The framing of ibogaine as an alternative to established treatments risks leading people away from life-saving evidence-based care; it is better understood as a complementary option with its own serious risks and specific indications.
Yes, ibogaine carries a genuine risk of death — primarily from cardiac arrhythmia (ventricular fibrillation or Torsades de Pointes), which is caused by its QTc-prolonging effect. The most frequently cited estimate of treatment-associated mortality in the pre-screening era is approximately 1 in 300 administrations; with proper cardiac screening, electrolyte correction, and monitoring, this figure is substantially reduced. Tracking exact mortality rates is difficult because most ibogaine treatment occurs outside registered clinical trials, in countries with variable reporting infrastructure. The documented cases share common factors: inadequate pre-treatment screening, unmanaged drug interactions (particularly with methadone), electrolyte imbalances, and absence of medical monitoring during the experience. These risks are largely, though not entirely, preventable with proper protocols.
Ibogaine is psychoactive and produces a profoundly altered state of consciousness at therapeutic doses, but its pharmacological mechanism differs fundamentally from serotonergic psychedelics. It is sometimes categorised as an "atypical psychedelic" or an "oneirogen" (dream-inducer). Its primary actions are at NMDA, kappa-opioid, and sigma receptors, not at 5-HT2A receptors. The phenomenological experience — waking dream imagery, life review, ataxia, intense sound sensitivity — is distinctive from psilocybin, LSD, or ayahuasca and should not be compared to them in terms of character, preparation, or outcome expectations.
First: consult with an addiction medicine physician before discontinuing any current medication, including methadone or buprenorphine. Abrupt discontinuation without medical supervision is dangerous. Second: research providers rigorously — use the GITA provider directory, verify that any clinic you consider offers mandatory pre-treatment ECG, electrolyte testing, continuous cardiac monitoring, and has medical personnel on-site. Third: ask about the integration programme — what support exists before and after the treatment itself? Providers without structured aftercare should be treated with significant scepticism. Fourth: consider clinical trial participation if you are in a jurisdiction where trials are recruiting — this offers research-grade safety protocols and typically at no cost. The MAPS Phase 2 ibogaine trial and the University of British Columbia's ibogaine programme (for veterans) are among those actively recruiting.
Bwiti is a living Indigenous spiritual tradition, not a historical practice. Its custodians — the Mitsogho, Fang, and related peoples of Gabon and Cameroon — retain sovereign authority over their knowledge, practice, and the iboga plant itself. Westerners engaging with ibogaine for addiction treatment or psychological healing are not participating in Bwiti — they are receiving a pharmacological treatment derived from a plant sacred to that tradition. Treating ibogaine with respect means acknowledging this: not appropriating Bwiti cultural forms, not claiming participation in a tradition one has not been initiated into, supporting Bwiti knowledge holders' rights and advocacy regarding iboga sovereignty, and where possible, contributing to sustainable iboga cultivation rather than fuelling pressure on wild populations. The Bwiti have explicitly called for recognition of their custodianship within international drug policy discussions; their voice belongs in those conversations.